Semen sperm samples will be collected from the male partner of couples that experience recurrent pregnancy loss. DNA analysis will be performed on the samples to investigate potential male factor causes of recurrent pregnancy loss.

Male partners of couples with recurrent pregnancy loss will be asked to provide two semen samples. The male partner will also be asked to complete the Charleston Co-Morbidity index at the time of the patient visit.

This is an observational registry with the goal of collecting data and biological samples that will support future research studies for Idiopathic Pulmonary Fibrosis (IPF) and other chronic fibrosing ILDs.

Participants will be required to answer questionnaires and have blood drawn every 6 months at their routine pulmonary clinic visits. Participants' de-identified health information will be entered into the a registry database by the study team every 6 months.

This is an international multi-centre, phase 3 randomized non-inferiority trial comparing induction FOLFOX/CAPOX chemotherapy followed by transanal endoscopic surgery (TES) to chemoradiation (chemoRT) followed by transanal endoscopic surgery (TES) in patients with cT1-T3ab*/N0 pMMR rectal adenocarcinoma.

Participants will receive chemotherapy with or without radiation for approximately 12 weeks. Once treatment is completed, they will have tests to see if the cancer is gone. Depending upon the scan results, the participant may have surgery or watch and wait. Total participant ime would be five years.

This study will compare Puxitatug Samrotecan vs. standard of care in the tretment of advanced endometrial cancer.

Participants will have two screening visits. One to sign a consent for testing of tumor tissue for B7-H4 mutation. If they have this mutation, you will come back to the clinic to sign a second consent to participate in the trial. At that time, you will have scans scheduled and blood work drawn to make sure it is safe for you to participate. After you have started study medication, you will be expected to keep all your study appointments, tell the study team how you are feeling and report on any medications you are taking.

This study will assess how healthy adults use vision and light touch at their fingertips (for example, as you might lightly touch a handrail) to help them maintain balance while they walk.

If you agree to participate, we will ask you to come to the lab in Rec Hall on Penn State's campus. First, we will ask you to complete a health history questionnaire, visual assessments, and physical assessments. We will also make measurements of your height, weight, and blood pressure. These assessments will help us determine if you are eligible to continue in the remainder of the study. After screening, if you meet the eligibility criteria, we will ask you to walk on various paths on a virtual reality treadmill under various conditions. Your task will be to walk normally and look forward in each condition. Treadmill walking will take less than an hour and breaks will be given as needed.

$20.00

Blood sugar spikes (i.e., acute hyperglycemia) are a common occurrence in individuals with metabolic dysfunction (i.e., prediabetes and type 2 diabetes). Previous research has shown that blood sugar spikes can temporarily worsen blood vessel health and function in healthy adults and individuals with metabolic dysfunction. Additionally, previous research suggests that blood sugar spikes can lead to elevated exercise blood pressure responses in healthy, college-aged adults. However, little is known about the impact of blood sugar spikes on cardiovascular responses to exercise (i.e., blood pressure and blood flow) in healthy middle-aged adults and individuals with metabolic dysfunction. The purpose of this study is to determine the impact of blood sugar spikes on cardiovascular responses during handgrip exercise. Participants will report to the lab for 3 sessions. Session 1 will be a baseline/control session. During sessions 2 and 3, participants will be randomly assigned to consume either a high-glucose beverage (75 g), or a high-fructose beverage (75 g). Glucose causes blood sugar spikes whereas fructose does not. Both before and after the consumption of either beverage, blood pressure, blood flow, and muscle oxygenation responses to handgrip exercise will be measured.

The study will include 3 sessions. Participants will report to the lab for 3 sessions. Session 1 will be a control session. During sessions 2 and 3, participants will be randomly assigned to drink a high-glucose beverage, or a high-fructose beverage. The measurements for this study will include body composition measurements, questionnaires, finger prick blood sampling to measure blood sugar levels, heart rate and blood pressure measurements, measurements of blood vessel health, and handgrip exercise with the measurement of blood pressure, blood flow, and muscle oxygen levels.

$75

The study is being done to learn how well tirabrutinib (investigational drug) works against cancer as compared to the combination of rituximab and temozolomide (comparator) in participants with PCNSL. We will also learn more about the safety of tirabrutinib and look at how tirabrutinib may affect the body.

To be in this study: o You must have confirmed PCNSL that has come back after treatment (relapsed) or has not improved with prior treatment (refractory) o You must have received methotrexate previously. You will be required to only take the assigned study drug to treat your cancer while on this study. If you believe that you will want to receive other therapy for your cancer, you should not participate in this study. You must agree to not participate in any other study while participating in this study or take any other therapy for your cancer while participating in this study.

This trial will be comparing a new drug against investigator's choice of therapy in the treatment of endometrial cancer that is HER 2 in addition to using a new assay to measure Her2

After the determination is made that it is safe for the patient to participate, the consent form will be signed, and the patient will have scans and blood work taken. The subject is expected to come to all study visits, report to the study team how they feel and let them know about any changes in medication. The study treatments will be given once a week for 21 or 28 days until the medication no longer works, you no longer want to take the medications, or the study doctor feels it is not safe for you to continue. After you complete treatment, you will be seen by the study team monthly for three months then followed for survival for 5 years.

$125 for every completed visit.

The GAME-ONc Study aims to explore how video games can support teens and young adults going through cancer treatment. We will talk with adolescents and young adults with cancer, their parents, and healthcare providers to better understand what emotional, social, and practical challenges young people face during treatment, and how a video game intervention might help. The study will also ask participants what kinds of game features they’d like to see, such as whether the game should be single-player or involve someone else, what topics it should include (like coping strategies, health behaviors, or ways to connect with others), and how to make it easy and enjoyable to use. Ultimately, the feedback from this project will guide the design of a video game prototype tailored for teenagers and young adults with cancer, setting the stage for future testing and development.

Participants will complete a brief demographic and gameplay preferences questionnaire and then take part in a one-time focus group session (approximately 1-1.5 hours) conducted via Microsoft Teams or in person. During the focus group, participants will discuss psychosocial needs of adolescents and young adults with cancer and share their opinions on desired features, content, and usability of a proposed video game intervention. The session will be audio and video recorded for research purposes.

100

The overall goal of this study is to determine the effects, good and/or bad, of a new treatment regimen that combines dasatinib or imatinib to chemotherapy with blinatumomab in patients with Ph+ and ABL-class Ph-like B-ALL. In this study, you will receive blinatumomab with chemotherapy and dasatinib or imatinib.

The overall goal of this study is to determine the effects, good and/or bad, of a new treatment regimen that combines dasatinib or imatinib to chemotherapy with blinatumomab in patients with Ph+ and ABL-class Ph-like B-ALL. In this study, you will receive blinatumomab with chemotherapy and dasatinib or imatinib. All patients on this study will receive the immunotherapy medicine blinatumomab in addition to chemotherapy plus dasatinib or imatinib. The treatment on this study takes about 2 years. It is divided into 7-8 phases of therapy. Participants will be asked to do some optional tests that will help to learn more about their immune system. To do these tests, we would like to take about 2 teaspoons (6-10 ml) of peripheral blood and about 1 teaspoon (3-5 ml) of bone marrow (at the time of standard procedures) at different time points. These tests will not require additional needle sticks or additional procedures. There will also be optional collection of bone marrow and/or blood for banking for future research.

Current concussion testing tracks physical symptoms like headaches but often misses psychological factors that can slow down healing. This study asks patients to respond to prompts regarding their injury in three timepoints: acute, sub-acute, and post-acute phases of injury. We will use artificial intelligence to look for specific patterns in their language that might predict a longer recovery. The goal is to create a simple screening tool that helps doctors identify patients who need extra support earlier."

There will be three surveys over the course of one month. Each survey will take around 10-15 minutes.

This is a dietary treatment study that looks into the effects of the consumption of yogurt on child brain activity, behavioral control, memory, and gut health. This knowledge may help us better understand the health benefits of fermented dairy like yogurt. 60 children, ages 8-10 years-old, will complete 2 in-lab sessions that include problem-solving games, learning tasks, and IQ tests. This study also uses child-friendly brain scanning technology that uses light to record brain activity. Between the two sessions, children will consume either 1-2 yogurt or juice beverages per day for 4-weeks and also collect a stool sample before each session. Throughout the study, parents and children will complete a series of surveys that assess child behaviors, behavioral control, sleep habits, and more.

We are looking for children to help us learn about how different beverages can affect brain and gut health. The study consists of 2 visits to our facility in Chandlee Lab, located on the University Park Campus. In both visits, your child will play problem-solving games, take an IQ test, and wear a functional near-infrared spectroscopy (fNIRS) cap which uses light to measure your child's brain activity while playing a computer game. You and your child will also fill out questionnaires. We will provide you with supplies of a beverage to take home that your child will drink each day between the 2 visits (about 4 weeks). We also ask that you collect two stool samples from your child using our provided stool sample collection kits.

$300.00-380.00

This study examines how children plan and correct their speech while describing pictures. Children between the ages of 6 and 8 will complete several language and thinking tasks and then describe pictures in different situations. Researchers will listen for natural speech behaviors such as pauses, repetitions, and self-corrections. The goal is to understand whether these speech patterns are related to children’s language abilities. The findings may help researchers and clinicians better understand how children produce sentences and may eventually support improved methods for identifying children who may need help with language development.

There will be one session (60-75 minutes including breaks) in person or via Zoom. Parent completes a 5-10 minute questionnaire. Child completes language tasks (TONI and TILLS subtests) and a picture description task with audio recordings. A second 45-minute session may be scheduled if the child needs a longer break in the first session or could not finish it.

$50

The purpose of this study is to find out if gene expression signatures are different in people with cancer associated dermatomyositis (CAM) and CAM negative (CAM-) patients. Dermatomyositis (DM) participants will provide up to 3 blood samples and 2 skin samples for testing, including testing that has to do with genes. Control participants (those who do not have a skin condition) will provide up to 2 skin samples for testing, including testing that has to do with genes.

Only control subjects are being recruited through StudyFinder. There will be one in-person visit where up to 2 skin samples will be collected using a punch biopsy.

$50.00 per skin sample

We are developing a tool to help parents of young children practice communication, relationship building, and listening skills.

This is an online study where parents will be asked how they might verbally respond to common situations that come up in everyday life. Participants will also complete questionnaires on their and their child's thoughts, feelings, and behaviors.

$100 maximum

Ewing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care. By incorporating eflornithine (DFMO) as an additional therapy and/or maintenance therapy we hope to safely observe improved event-free survival and overall survival. There are 5 cohorts covered under this master protocol.

Patients will come in for screening and at the start of the study, and then approximately once a month during chemotherapy (if applicable). Patients may need to be seen more often for standard of care. During the DFMO alone phase, patients will come in once a month for the first 3 months, and then once every 3 months until the end of study treatment. During these visits patients will have tests done which may include a physical exam, blood tests, cardiac tests, hearing tests, or tumor evaluations.

We will utilize natural language processing using artificial intelligence to analyze text responses to open-ended survey questions. The population will be people who have experienced persistent symptoms following a concussion (more than three months), at any time in their life. We will also collect symptom data. The goal is to compare the symptom data between participants with cognitive distortions in their language compared to those with healthy language patterns.

Participants will complete one online survey using Qualtrics. If they choose to, they can be redirected to a gift card drawing after completing the survey.

In this project, we will study how elementary school aged children engage with our AI-integrated STEM learning materials. AI will be used as part of learning, particularly focusing on functions of converting text to images, storybooks, and videos.

If you participate, you will complete a survey, participate in an AI-integrated STEM learning session, and complete an interview (2 hours in total) on Penn State University Park campus or Penn State Hazleton campus.

$75

Participants will be asked to use a nicotine pouches, with either 3, 6, or 9mg of nicotine, in the laboratory while blood samples are collected. The study will measure the nicotine delivery and related effects of using nicotine pouches among current tobacco product users.

Participants will be asked to attend one study visit lasting approximately 1.5 hours. Participants will be asked to use a nicotine pouch in either 3, 6, or 9mg of nicotine while blood samples are collected.

175

The purpose of this Expanded Access Program is to determine the safety of cretostimogene in patients with BCG -unresponsive high-risk Non Muscle Invasive Bladder Cancer and to determine the Complete Response rate at any time of cretostimogene in patients with BCG-unresponsive CIS with or without HG Ta/T1 papillary NMIBC

Eligible participants will receive the study drug, Cretostimogene every week for 6 treatments, followed by a maintenance period as directed by the Investigator. There are 3 phases in the study: Screening Phase, Treatment Phase, and Follow-Up Phase. The Screening Phase will last up to 16 weeks (4 months). The Treatment Phase can continue for up to 2 years from the start of study treatment unless your cancer gets worse or recurs. The Follow-Up Phase will include one visit every 3 months after the last study treatment. If your cancer has not come back but you stop treatment before the end of the Treatment Phase, you will also have a study visit every 3 months in the Follow-Up Phase to confirm whether your cancer gets worse or recurs, until 2 years after the start of treatment. If your cancer has gotten worse or recurs at any point during the study, you will not be scheduled to return to the clinic/hospital for the study after the final visit, but you will be contacted approximately every 6 months.

Physical activity is the cornerstone of overall health and well-being and is associated with better survival and survivorship outcomes in pediatric cancer patients. This research is being conducted to identify biomarkers associated with the physical activity status of 90 children diagnosed with leukemia undergoing therapy.

During the first visit, you will answer demographic questions and provide medical history. You will then be asking to wear a Fitbit for at least 7 consecutive days, and participating in a second visit to collect saliva and blood samples

This trial will examine if the dose of drug determined in the Phase `1 portion can stop the cancer from growing.

There will be a screening period after you sign consent. You will have labs drawn and scans done to make sure it is safe for you to participate in this study. During the first 2 cycles, you will need to come to the clinic a total of 6 times. We do this to make sure you are feeling ok while taking these study medications. From C3 onward you will only need to come into the clinic twice. You will need to keep all of your clinic appointments, tell the study doctor how you are feeling and make sure that you tell them about any and all medications you are taking.

This a pilot study that will evaluate how feasible it is to use a questionnaire on paper, tablet or QR code to assess what barrier patient face to enroll in clinical trials at PSCI

Patient will fill out a 5 minute survey either on paper, tablet or on their own device.

The purpose of this clinical trial is to check the effect RBS2418 in combination with tremelimumab and durvalumab (referred to as STRIDE) may have on cancer and to determine which of the two RBS2418 doses is better and will be selected for further investigation.

Participation may last up to approximately 27-30 months and require several visits depending on how you do on the study, with each visit expected to take 2-4 hours unless you agree to participate in the subgroup that requires more blood collection. Blood will be drawn at each visit. Participants may also have to provide urine samples. A tumor specimen will be required at the screening visit. Optional specimens may be taken over the course of the study, if agreed upon. Every 6-8 weeks, a tumor scan will be completed. If the participant is assigned to Arm A or B, they will take the study drug daily, and all participants will have one infusion of tremelimumab and monthly infusions of durvalumab.

This study examines how individuals use general-purpose AI chatbots (e.g., ChatGPT, Gemini, Claude) when responding to personal, emotional, or difficult experiences, including experiences of victimization. Participants complete an anonymous online survey taking approximately 15–20 minutes covering patterns of chatbot use, emotional responses to these interactions, and help-seeking behavior. The study is open to all adults 18 and older. Participants may optionally enter a raffle for one of ten $25 Amazon e-gift cards.

Completing a brief, anonymous online survey that takes approximately 15–20 minutes.

This trial are looking at GIREDESTRANT to see if that combined with another drug, will work better and keeping breast cancer in remission after progressing on a CDK inhibitor.

Participants must come into the clinic to learn about the study and sign consent. Once it has been determined that it is safe to participate, participants must come to the clinic every other week for the first two cycles for a check up to see how they are feeling. This way the study doctors knows that it is safe to continue the study drugs. After the first two cycles you will come to the clinic once a month. You will have a physical exam, blood drawn and periodically through the study, scans to see how your cancer is responding to the study treatment. You will continue on the study therapy until your cancer no longer responds to it, you do not want to take the treatment any more or the study doctor feels it is unsafe for you to continue the study treatment.

To see if giving ovarian suppression subcutaneously at a different dose will adequately cause ovarian suppression in HR+ HER2 negative women

Once it has been determined that it is safe for your to participate, you will come in to the clinic about 5 times over the course of 168 days. On days one and 85 you will receive a shot of the study drug. You will need to tell the study team how you feel and all medications that you are taking.

$46/visit for travel reimbursement. You will need to provide receipts.

The purpose of this voluntary research study is to find out if cemiplimab and fianlimab with or without ipilimumab can shrink or stop advanced or metastatic clear cell kidney cancer from growing. This research study will include a screening period, a treatment period, and a follow up period, and participation may last up to five years

Participant will need to complete several screening tests. If participant qualifies for the study, participant will be asked to receive one of the study treatment combinations. Cemiplimab, fianlimab, and ipilimumab, or Cemiplimab and fianlimab, or Ipilimumab and nivolumab. Participant will continue receiving assigned combination for up to 96 weeks (about 22 months). Have regular tests and assessments, which may include physical exams, blood tests, imaging scans, and other procedures needed for your safety and for study purposes.

This is a Phase 3 study for Induction treatment of ulcerative colitis to evaluate safety and efficacy of duvakitug. The subjects are going to be enrolled in either the open label induction (Study-1), or placebo controlled induction (Study-2) across the study sites. All the participants who respond to treatment can be randomized into maintenance treatment.. The participants who do not respond to treatment will be eligible for an extended induction. The subjects must sign the informed consent before any procedures. the screening period will be for 5 weeks, and the Induction treatment will last 12 weeks. There will be six drug administrations in the induction treatment by subcutaneous injections. The participants will have in person visits, and will have procedures done such as blood draws, physical examination, endoscopy with biopsies, and completing questionnaires.

Participants will attend in person visit at the research clinical facility in Hershey, PA. If they sign the informed consent and want to participate, they will have vital checked, physical examination done. They will provide specimens such as blood and stool. They will answer questionnaires at home and in the clinic. The endoscopy will be done with biopsy to evaluate the disease response to the treatment. The drug will be administered by subcutaneous injection in the clinic. There will be a compensation for every completed visit.

$1400

The goal of this project is to better understand identity construction during the transition to parenthood and examine factors that facilitate the development of supportive coparenting relationships. Additionally, this study will leverage an AI tool to conduct AI-moderated interviews with new parents.

New parents will be asked to complete an AI-moderated interview about their experiences as a new parent and an online survey.

25